Advertisement

Familial Cancer

, Volume 7, Issue 1, pp 53–58 | Cite as

Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis

  • Karen H. Lu
Article

Abstract

The main cancer susceptibility syndromes that involve gynecologic cancers include Breast-Ovarian Cancer Syndrome and Lynch Syndrome/Hereditary Non-polyposis Colorectal Cancer Syndrome. For uterine cancer, approximately 5% of all cases are likely due to a hereditary cause and for ovarian cancer, approximately 10% are due to an inherited cause. Gynecologic oncologists play an important role in identifying women with ovarian or endometrial cancer who may have these syndromes. Personal and family history of relevant cancers assists with identification. For those women without cancer who are found to have a hereditary cancer syndrome, effective counseling in the prevention and early detection of cancers is crucial.

Keywords

Lynch syndrome Ovarian cancer Endometrial cancer BRCA1 

References

  1. 1.
    Jemal A et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRefGoogle Scholar
  2. 2.
    Aarnio M et al (1999) Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 81(2):214–218PubMedCrossRefGoogle Scholar
  3. 3.
    Dunlop MG et al (1997) Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet 6(1):105–110PubMedCrossRefGoogle Scholar
  4. 4.
    Lu K et al (2004) Gynecological malignancy as a “Sentinel Cancer” for women with HNPCC. Gynecol Oncol 92:421Google Scholar
  5. 5.
    Umar A et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96(4):261–268PubMedCrossRefGoogle Scholar
  6. 6.
    Berends MJ et al (2003) Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol 21(23):4364–4370PubMedCrossRefGoogle Scholar
  7. 7.
    Lu K, S.J., Rodabaugh K, Sun C, Daniels MS, White KG, Soliman PT, Luthra R, Broaddus RR. Defining criteria for Lynch Syndrome/HNPCC in women under 50 with endometrial cancer: Final results of a prospective, multi-center study. in 1st Conference of InSIGHT, the International Society for Gastrointestinal Hereditary Tumors. 2005. Newcastle, UK: Familial CancerGoogle Scholar
  8. 8.
    Millar AL et al (1999) Mismatch repair gene defects contribute to the genetic basis of double primary cancers of the colorectum and endometrium. Hum Mol Genet 8(5):823–829PubMedCrossRefGoogle Scholar
  9. 9.
    Soliman PT et al (2004) Synchronous primary cancers of the endometrium and ovary: a single institution review of 84 cases. Gynecol Oncol 94(2):456–462PubMedCrossRefGoogle Scholar
  10. 10.
    Burke W et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. Cancer Genetics Studies Consortium. JAMA 277(12):997–1003PubMedCrossRefGoogle Scholar
  11. 11.
    NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Vol. Version 1.2006. 2006, Rockledge, PA: National Comprehensive Cancer NetworkGoogle Scholar
  12. 12.
    Lu KH, Soliman PT, Boyd-Rogers SG, Daniels MS, Broaddus RR, Lynch PM, Peterson SK (2005) A prospective pilot study of combined colon and endometrial cancer screening in women with HNPCC. Familial Cancer 4:104–105Google Scholar
  13. 13.
    Combination oral contraceptive use and the risk of endometrial cancer (1987) The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 257(6):796–800CrossRefGoogle Scholar
  14. 14.
    Schmeler KM et al (2006) Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 354(3):261–269PubMedCrossRefGoogle Scholar
  15. 15.
    Chung L et al (2003) Unexpected endometrial cancer at prophylactic hysterectomy in a woman with hereditary nonpolyposis colon cancer. Obstet Gynecol 102(5 Pt 2):1152–1155PubMedCrossRefGoogle Scholar
  16. 16.
    Frank TS et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425PubMedGoogle Scholar
  17. 17.
    Lu KH et al (1999) A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol 93(1):34–37PubMedCrossRefGoogle Scholar
  18. 18.
    Moslehi R et al (2000) BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 66(4):1259–1272PubMedCrossRefGoogle Scholar
  19. 19.
    Metcalfe KA et al (2005) The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecol Oncol 96(1):222–226PubMedCrossRefGoogle Scholar
  20. 20.
    Levine DA et al (2003) Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 21(22):4222–4227PubMedCrossRefGoogle Scholar
  21. 21.
    Gaarenstroom KN et al (2006) Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. Int J Gynecol Cancer 16 Suppl 1:54–59PubMedCrossRefGoogle Scholar
  22. 22.
    Meeuwissen PA et al (2005) Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol 97(2):476–482PubMedCrossRefGoogle Scholar
  23. 23.
    Stirling D et al (2005) Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23(24):5588–5596PubMedCrossRefGoogle Scholar
  24. 24.
    The reduction in risk of ovarian cancer associated with oral-contraceptive use (1987) The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 316(11):650–655CrossRefGoogle Scholar
  25. 25.
    Narod SA, Sun P, Risch HA (2001) Ovarian cancer, oral contraceptives, and BRCA mutations. N Engl J Med 345(23):1706–1707PubMedCrossRefGoogle Scholar
  26. 26.
    Whittemore AS et al (2004) Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. Br J Cancer 91(11):1911–1915PubMedCrossRefGoogle Scholar
  27. 27.
    Modan B et al (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345(4):235–240PubMedCrossRefGoogle Scholar
  28. 28.
    Narod SA et al (2002) Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 94(23):1773–1779PubMedGoogle Scholar
  29. 29.
    Rebbeck TR et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346(21):1616–1622PubMedCrossRefGoogle Scholar
  30. 30.
    Kauff ND et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–15PubMedCrossRefGoogle Scholar
  31. 31.
    Schmeler KM et al (2006) Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstet Gynecol 108(3):515–520PubMedGoogle Scholar
  32. 32.
    Rebbeck TR et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23(31):7804–7810PubMedCrossRefGoogle Scholar
  33. 33.
    Lu KH et al (2000) Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 18(14):2728–2732PubMedGoogle Scholar
  34. 34.
    Colgan TJ et al (2001) Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 25(10):1283–1289PubMedCrossRefGoogle Scholar
  35. 35.
    Powell CB et al (2005) Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol 23(1):127–132PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media B.V. 2007

Authors and Affiliations

  1. 1.Department of Gynecologic Oncology, Clinical Cancer GeneticsU.T. M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations